EP-Solutions Announces €10M Capital Increase
Summary
EP-Solutions SA, an Yverdon Les Bains, Switzerland-based developer of innovative methods for non-invasive diagnostics and for interventional treatment of cardiac arrhythmias, announced a capital increase of €10M.The company intends to use the funds for the further development and clinical roll-out in Europe and the USA of the second generation AMYCARD system, a CE Mark-approved diagnostic device.Led by Dr. Werner Rainer, board member and CEO ad interim, Dr. Joaquin Azpilicueta, MD, MBA as COO, and Drago A. Cerchiari, Ph.D., chairman of the board, EP-Solutions is primarily focused on the The EP-Solutions system allowing for simultaneous electrophysiology mapping on both epicardial and endocardial surfaces of the heart.The company’s real-time cardiac mapping technology is based over 6 years of clinical research with more than 750 patients.Founded in 2009 under the name of Amycard, EP-Solutions was then incorporated in Switzerland as EP-Solutions after the acquisition and transfer of assets of Amycard.